礼来与诺和诺德在最新财报发布后差距进一步拉大

2026-08-06 · cnbc.com

随着礼来在肥胖症药物竞赛中扩大领先优势，诺和诺德仍在努力夺回市场份额并恢复投资者对其研发管线的信心。

"While Novo raised guidance (as expected), the pipeline and path to sustainable growth remain less clear," BMO Capital Markets analyst Evan Seigerman said in a ...